Filgrastim shortage — DE supply status & alternatives

Filgrastim

—

🇦🇺 AUST R 366760 · Cipla Australia Pty Ltd

In supply · Australia

Accofil

In supply · 🇦🇺 Australia · short in🇩🇪 DE🇬🇷 GR

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$58.73details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)

Brand names	Accofil

Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Marketing-authorisation holders	Cipla Australia Pty Ltd, Amgen Australia Pty Ltd, Pfizer Australia Pty Ltd, Teva Pharma Australia Pty Ltd +5 more

Registrations on file	21

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$58.73

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

filgrastim 300 microgram/0.5 mL injection, 5 x 0.5 mL syringes

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 4 resolved events

◷

~1 month

Historical pattern from resolved shortage records — not a prediction of this event.

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Feb 2015

Latest approval

Shortage status by regulator official notices

🇬🇷

EOF · 2d ago

Medium

🇩🇪

Germany

BfArM · 13d ago

Medium

🇮🇹

Italy

AIFA · 4h ago

Resolved

🇦🇺

Australia

TGA · 1d ago

Resolved

Recalls official enforcement reports

🇺🇸

NEUPOGEN

Amgen, Inc. · Feb 2025

Class IIdetails ↗

🇺🇸

NEUPOGEN

Amgen, Inc. · Feb 2025

Class IIdetails ↗

🌐

Grastofil

Accord Healthcare S.L.U. · Jan 2025

Class Unifieddetails ↗

🌐

Biograstim

AbZ-Pharma GmbH · Sept 2015

Class Unifieddetails ↗

🌐

Filgrastim ratiopharm

Ratiopharm GmbH · Apr 2011

Class Unifieddetails ↗

Verified timeline regulator events

🇩🇪 28 Apr 2026

medium reported

🇬🇷 24 Apr 2026

medium reported

🇬🇷 6 Apr 2026

Shortage resolved

🇦🇺 2 Apr 2026

Shortage resolved

🇬🇷 27 Jan 2026

Shortage resolved

🇬🇷 19 Jan 2026

Shortage resolved

Sources official regulators

🇮🇹

AIFA

verified 4h ago

verify ↗

🇦🇺

TGA

verified 1d ago

verify ↗

🇬🇷

EOF

verified 2d ago

verify ↗

🇩🇪

BfArM

verified 13d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders21 registrations · 9 MA holders

Product	Strength	Form	Market	MA holder	Status
FILPEGLA pegfilgrastim	6 mg	—	🇦🇺 AU	Cipla Australia Pty Ltd	Active
NEUPOGEN filgrastim	480 microgram	—	🇦🇺 AU	Amgen Australia Pty Ltd	Active
NEUPOGEN filgrastim	300 microgram	—	🇦🇺 AU	Amgen Australia Pty Ltd	Active
NEULASTA pegfilgrastim rbe	6mg	—	🇦🇺 AU	Amgen Australia Pty Ltd	Active
NEULASTA pegfilgrastim	6mg	—	🇦🇺 AU	Amgen Australia Pty Ltd	Active
NIVESTIM filgrastim 300microgram/	300microgram	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
NIVESTIM filgrastim 120microgram/	120microgram	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
NIVESTIM filgrastim 480microgram/	480microgram	—	🇦🇺 AU	Pfizer Australia Pty Ltd	Active
TEVAGRASTIM filgrastim	300 microgram	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
TEVAGRASTIM filgrastim	480 microgram	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
ZARZIO filgrastim	480 microgram	—	🇦🇺 AU	Sandoz Pty Ltd	Active
ZARZIO filgrastim	300 microgram	—	🇦🇺 AU	Sandoz Pty Ltd	Active
LONQUEX lipegfilgrastim	6 mg	—	🇦🇺 AU	Teva Pharma Australia Pty Ltd	Active
RISTEMPA pegfilgrastim	6mg	—	🇦🇺 AU	Amgen Australia Pty Ltd	Active
ZIEXTENZO pegfilgrastim	6mg	—	🇦🇺 AU	Sandoz Pty Ltd	Active

+6 more registrations on file

Mederti Drug Report

Generated 4 July 2026 · Australia market · 4 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.